A recent study reveals that individuals who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Findings released in a leading health publication shows that while obese people frequently drop about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such treatments must be informed of the danger of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a return to original weight within about one and a half years.
Comparing Approaches
The study, which examined 37 of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers note that individuals who shed pounds through lifestyle changes alone generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Explaining the Fast Regain
Nutrition scientists suggest the way of the injections is key to understanding the accelerated regain.
The injections mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Issue?
Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of weight regain, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who say that the results "highlight the long-term nature of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the medication explain a sudden return of cravings.
"It felt as if a trigger flipping and you become starving," described an individual.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.
Significant Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and long-term success hinges on integrated behavioural changes.
